CERo Therapeutics Secures Up to $11.67 Million SRX Financing, Consolidates $5.67 Million DebtTradingView·16 hours agoCERO+18.87%
SRX Global sells 3,579 Series C preferred shares in private placement valued at $2.86 millionPUBT·Aug 28 at 09:03 PMSRXH-1.75%CERO+18.87%
Cero Therapeutics Q2 FY26 net loss narrows 81% to $1.03 million; R&D expenses fall 37% to $1.74 millionPUBT·Aug 14 at 08:12 PMCERO+18.87%
Cero Therapeutics Secures $2.09M 10% Convertible Note With SRX Global, Maturing May 2027TradingView·Jul 17 at 08:43 PMCERO+18.87%SRXH-1.75%
Delisting of Securities from The Nasdaq Stock Market | NDAQ Stock NewsStockTitan·Jul 10 at 08:00 AMBTM0.00%BOWN0.00%
Cero Therapeutics amends SRX Health promissory note, lifts borrowing capacity to $1.41 millionPUBT·Jun 26 at 08:06 PMCERO+18.87%SRXH-1.75%
CERo Therapeutics Announces Clinical Update from CERTAIN-T Phase 1 CER-1236 Trial, Including Patient Undergoing Allogeneic Stem Cell Transplant Following TreatmentUnusual Whales·Jun 15 at 12:16 PMCERO+18.87%
CERo Therapeutics Completes Second Ascending Dose Cohort of Phase 1 CER-1236 Trial | CERO Stock NewsStockTitan·May 11 at 04:15 AMCERO+18.87%BBH-0.03%
CERo Therapeutics Doses Third Patient in Cohort 2 of Phase 1 CER-1236 Trial | CERO Stock NewsStockTitan·Apr 14 at 04:15 AMCERO+18.87%IBB+0.05%
Cereno Scientific Reports Favorable Safety and Tolerability after 12 Months of CS1 Treatment in PAH from the Expanded Access Program | B Stock NewsStockTitan·Mar 30 at 11:15 PMCERO+18.87%BBH-0.03%
